# Atea Pharmaceuticals Inc. (AVIR)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $387M  
**Price:** $4.39 (+0.69%)

> Atea Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing oral antiviral therapeutics to address serious viral infections. Its primary product candidate, bemnifosbuvir, a nucleotide NS5B inhibitor, targets COVID-19 caused by SARS-CoV-2 and its variants. The company is also advancing bemnifosbuvir in combination with ruzasvir, an NS5A inhibitor, for hepatitis C virus treatment, with this regimen currently in Phase 3 clinical trials. Additionally, Atea Pharmaceuticals develops AT-587 for chronic hepatitis E virus infection, which is in Phase 1 trials. Operating within the biotechnology sector of healthcare, the company holds a license agreement with MSD International GmbH for ruzasvir's development, manufacture, and commercialization. Founded in 2012 and headquartered in Boston, Massachusetts, Atea Pharmaceuticals plays a key role in advancing innovative oral therapies for viral diseases affecting global patient populations.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2021 | $351M | — | $138M | $121M | — |
| 2020 | $49M | — | -$11M | -$11M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2021 | $773M | $63M | $710M | $764M | — |
| 2020 | $864M | $316M | $548M | $850M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$132M | — | — |
| 2024 | -$135M | — | — |
| 2023 | -$85M | — | — |
| 2022 | -$121M | $2M | -$123M |
| 2021 | -$87M | $4,000 | -$87M |
| 2020 | $297M | $26,000 | $297M |
| 2019 | -$13M | $2,000 | -$13M |
| 2018 | -$8M | $12,000 | -$8M |

Source: [CompaniesByCap](https://companiesbycap.com/company/AVIR)